Icatibant Universal Farma (Icatibant)

Icatibant is a competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary drivers of swelling in hereditary angioedema.

The dose of icatibant is determined by the prescribing healthcare professional based on the patient’s clinical condition and regulatory guidelines. The prescriber will decide the exact amount and frequency required for each acute HAE episode.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other approved HAE therapies include C1‑esterase inhibitor concentrates and kallikrein inhibitors. Icatibant is administered subcutaneously and provides rapid symptom relief, while the alternatives may be given intravenously or have different mechanisms of action.

Icatibant should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not use the medication if it has been exposed to temperatures outside the recommended range.

Icatibant is supplied as a sterile solution for subcutaneous injection. The prescribed dose is injected into the abdominal wall or thigh using a pre‑filled syringe or autoinjector, following the instructions provided by the healthcare professional.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, systemic angioedema unrelated to the HAE episode, and sudden hypotension. Patients should be monitored closely after injection and seek immediate medical attention if any severe symptoms develop.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients receiving ACE inhibitors, estrogen therapy, or other bradykinin B2 antagonists, as these combinations may increase the risk of adverse reactions.